What are the doses and indications for potassium-sparing diuretics, including spironolactone (Aldactone) and eplerenone?

Potassium-Sparing Diuretics: Doses and Indications

Potassium-sparing diuretics should be prescribed based on specific indications with careful attention to dosing, monitoring, and potential adverse effects, particularly the risk of hyperkalemia. 1

Types of Potassium-Sparing Diuretics

Aldosterone Antagonists

• Spironolactone

  • Heart Failure: Start at 25 mg once daily (12.5 mg if concerns about hyperkalemia); target dose 50 mg once daily 1, 2
  • Hypertension: 25-100 mg daily in single or divided doses; doses >100 mg generally don't provide additional BP reduction 2, 3
  • Edema in Cirrhosis: 25-200 mg daily, initiate in hospital setting and titrate slowly 2
  • Primary Hyperaldosteronism: 100-400 mg daily 2
  • Resistant Hypertension: 25-50 mg daily 3

• Eplerenone

  • Heart Failure post-MI: Start at 25 mg once daily, titrate to 50 mg once daily within 4 weeks 4
  • Hypertension: 50 mg once daily; may increase to 50 mg twice daily for inadequate response 4
  • Resistant Hypertension: Alternative to spironolactone when sexual side effects occur 3

Other Potassium-Sparing Diuretics

• Amiloride: 5-10 mg once or twice daily 1
• Triamterene: 50-100 mg once or twice daily 1

Primary Indications

Heart Failure

• Spironolactone and Eplerenone are indicated for:
  • LVEF ≤35% 1
  • Moderate to severe symptoms (NYHA class III-IV) 1
  • Patients on optimal doses of beta-blockers and ACE inhibitors or ARBs 1
  • Eplerenone specifically for post-MI heart failure with reduced ejection fraction 4

Hypertension

• All potassium-sparing diuretics can be used for:
  • Essential hypertension, particularly low-renin and salt-sensitive forms 1, 3
  • Resistant hypertension (particularly aldosterone antagonists) 1, 3
  • Combination therapy with thiazide diuretics to prevent hypokalemia 3, 5

Other Indications

• Primary aldosteronism: Spironolactone is preferred (100-400 mg daily) 1, 2
• Edema in cirrhosis: Spironolactone (25-200 mg daily) 2
• Prevention of diuretic-induced hypokalemia: All potassium-sparing diuretics 5

Monitoring and Safety Considerations

Before Initiating Therapy

• Check baseline renal function and serum electrolytes 1, 6
• Ensure serum potassium ≤5.0 mmol/L 1
• Ensure creatinine <2.0-2.5 mg/dL (or eGFR >30 mL/min) 1, 6
• Avoid in patients with severe renal dysfunction (eGFR <30 mL/min) 1, 6

During Therapy

• Monitor serum potassium and renal function:
  • 1 and 4 weeks after starting treatment 1
  • 1 and 4 weeks after dose increases 1
  • Monthly for first 3 months, then every 3-6 months 1
• Discontinue or reduce potassium supplements when starting therapy 1, 6
• Consider reducing doses of other diuretics (e.g., furosemide) by 25-50% when initiating aldosterone antagonists 6

Management of Adverse Effects

• Hyperkalemia:
  • If K+ >5.5 mmol/L: Halve dose (e.g., 25 mg on alternate days) 1
  • If K+ ≥6.0 mmol/L: Stop medication immediately 1, 7
• Worsening renal function:
  • If creatinine rises to >220 μmol/L (2.5 mg/dL): Halve dose 1
  • If creatinine rises to >310 μmol/L (3.5 mg/dL): Stop medication 1
• Sexual side effects (with spironolactone):
  • Breast discomfort/enlargement in men (10% with spironolactone) 1
  • Consider switching to eplerenone if these occur 1, 8

Special Considerations

High-Risk Patients for Hyperkalemia

• Elderly patients 1, 7
• Patients with diabetes 1, 7
• Patients with renal insufficiency 1, 7
• Patients taking ACE inhibitors or ARBs 1, 7
• Patients taking NSAIDs 1
• Patients at risk for dehydration 7

Relative Potency

• Spironolactone is approximately 4 times more potent than triamterene for potassium retention 5
• Equivalent doses: spironolactone 50 mg ≈ triamterene 200 mg ≈ amiloride 20 mg 5

Practical Tips

• For patients with eGFR 30-49 mL/min/1.73m², consider starting at lower doses:
  • Spironolactone 25 mg every other day 1, 2
  • Eplerenone 25 mg every other day 6
• Instruct patients to temporarily stop aldosterone antagonists during episodes of diarrhea, dehydration, or when loop diuretic therapy is interrupted 1
• Avoid triple combination of ACE inhibitor, ARB, and aldosterone antagonist due to high risk of hyperkalemia 1, 7